PTGX - Company ID 0001377121
The table below shows Protagonist Therapeutics, Inc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $56.37M | $4.71M | $5.55M | $28.32M | $4.67M | $4.17M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $46.74M | $40.00M | $37.04M | $35.89M | $35.97M | $33.52M |
Protagonist Therapeutics, Inc reported annual revenue of $46.02M for fiscal year 2025. That is down 89.4% from $434.43M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $20.06M (FY 2017) to $46.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $13.28M |
| $11.13M |
| $10.55M |
| $11.74M |
| $10.16M |
| $9.44M |
| Operating income | -$3.65M | -$46.42M | -$42.04M | -$19.31M | -$41.45M | -$38.79M |
| Income tax | -$1.50M | $0.00 | $172.00K | $0.00 | -$420.00K | -$676.00K |
| Net income | $3.78M | -$39.34M | -$34.77M | -$11.65M | -$33.21M | -$30.62M |
| EPS (diluted) | $0.05 | -$0.62 | -$0.55 | -$0.19 | -$0.54 | -$0.50 |